title: Interleukin-2 activation of haematopoietic stem cells.
abstract: BACKGROUND
  Recent findings concerning the role of immunity in the eradication of residual malignant disease after autologous haematopoietic stem cell transplantation have led to extensive studies of T-cell and natural killer (NK) mediated anti-tumour effects. Interleukin 2 (IL-2) activation of autologous bone marrow (BM) or peripheral blood stem cells (PBSC) before transplantation is one of the methods of adoptive cell therapy.
  
  
  METHODS
  Autologous BM of patients with chronic myelogenous leukaemia (n = 11) and PBSC of patients with multiple myeloma (n = 14) were activated by IL-2 in laboratory conditions with the aim of evaluating the feasibility of this method, the activation of T and NK cells, recovery of active progenitor cells, microbial contamination, and reduction of malignant cell content.
  
  
  RESULTS
  Samples of BM (mean 2.6 x 10(6) cells) and PBSC (mean 10.3 x 10(6) cells) were cultured in complete culture medium with IL-2 (6000 Ul/ml) for 24 h. The recovery of CD34+ cells and CFU-GM was 82.5% and 51.5%, respectively, for BM, and 85% and 86%, respectively, for PBSC (mean values). No purging effect was detected by flow cytometry and a small decline in malignant cell contamination was observed by quantitative PCR in BM samples. No microbial contamination occurred during the sample processing.
  
  
  CONCLUSIONS
  The described in vitro activation of BM and peripheral blood stem cells using IL-2 was evaluated as a safe and reliable method suitable for clinical application.
authors.affiliation: Department of Internal Medicine-Hematooncology, Department of Clinical Hematology, University Hospital Brno, Bohunice, Jihlavská 20, CZ-639 00 Brno, Czech Republic. r.hajek@fnbrno.cz
authors.forename: R
authors.initials: R
authors.lastname: Hájek
authors.forename: Z
authors.initials: Z
authors.lastname: Korístek
authors.forename: J
authors.initials: J
authors.lastname: Vinklárková
authors.forename: E
authors.initials: E
authors.lastname: Janovská
authors.forename: M
authors.initials: M
authors.lastname: Klabusay
authors.forename: M
authors.initials: M
authors.lastname: Doubek
authors.forename: D
authors.initials: D
authors.lastname: Dvoráková
authors.forename: L
authors.initials: L
authors.lastname: Bourková
authors.forename: L
authors.initials: L
authors.lastname: Dusek
authors.forename: T
authors.initials: T
authors.lastname: Büchler
authors.forename: J
authors.initials: J
authors.lastname: Adler
authors.forename: Z
authors.initials: Z
authors.lastname: Adam
authors.forename: M
authors.initials: M
authors.lastname: Penka
authors.forename: J
authors.initials: J
authors.lastname: Mayer
authors.forename: J
authors.initials: J
authors.lastname: Vorlícek
mesh_terms: D001853:Bone Marrow / Q000473:pathology; D001854:Bone Marrow Cells / Q000187:drug effects / Q000276:immunology*; D002478:Cells, Cultured; D005434:Flow Cytometry; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000276:immunology*; D007376:Interleukin-2 / Q000494:pharmacology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D018655:Lymphocyte Count; D009101:Multiple Myeloma / Q000097:blood*; D016133:Polymerase Chain Reaction; D012044:Regression Analysis
chemical_list: D007376:Interleukin-2